IDEAYA Biosciences, a Phase 1 biotech developing targeted therapies for genetically-defined cancers, raised $50 million by offering 5 million shares at $10, below the range of $13 to $15. Insiders had intended to purchase up to $35 million of the IPO. IDEAYA Biosciences plans to list on the Nasdaq under the symbol IDYA. J.P. Morgan, Citi and Jefferies acted as lead managers on the deal.
